Instrument Inactif

Communiqués pSivida Corp. Nasdaq

Actions

US74440J1016

Recherche biotechnologique et médicale

Communiqués

09/08/16	PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	PU
14/07/16	PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	PU
02/05/16	PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	PU
28/09/15	PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	BU
14/09/15	PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	BU
09/09/15	PSivida : Provides Company Update and Reports Fourth Quarter and FY 2015 Results	BU
03/09/15	PSivida : CEO Invited to Speak at Surfaces in BioMaterials Foundation's BioInterface 2015 Annual Symposium	PU
03/09/15	PSivida : CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium	BU
02/09/15	PSivida : Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information	BU
21/07/15	PSivida : CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend	BU
13/07/15	PSivida : Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis	BU
07/07/15	PSivida : Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week	BU
24/06/15	PSivida : CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015	BU
19/05/15	PSivida : Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis	BU
12/05/15	PSivida : Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company	BU
08/05/15	PSivida : Reports Third Quarter FY 2015 Results	BU
01/05/15	PSivida : Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information	BU
18/04/15	PSivida : Reports ILUVIEN® for DME Approved in Poland	PU
14/04/15	PSivida : Reports ILUVIEN® for DME Approved in Poland	BU
26/03/15	PSivida : Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis	BU
17/02/15	PSivida : Announces U.S. Shipments of ILUVIEN® for DME to Start February 23	BU
05/02/15	PSivida : Reports Second Quarter FY 2015 Results	BU
03/02/15	PSivida : CEO to Present at 17Th Annual BioCEO & Investor Conference February 9	BU
30/01/15	PSivida : Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information	BU
26/01/15	PSivida : Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries	BU